TechSeeker Profile

Exelixis Inc
Profile last edited on: 2/10/2017

NO Business Identifier is currently available for this company.
TS Type
Small Corporation
Status
Year Founded
1994
Last Involved Year
2002

Key People / Management

Location Information

210 East Grand Avenue
South San Francisco, CA 94080
   (650) 837-7000
   www.exelixis.com

Public Profile

Exelixis, Inc. (Nasdaq: EXEL) is a genomics-based drug discovery, biopharmaceutical company focused to the discovery, development and promotion of new medicines with the potential to improve care and outcomes for people with cancer. Since its founding, three medicines discovered at Exelixis have progressed through clinical development to receive regulatory approval. Currently, Exelixis is focused on advancing cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors, which has shown clinical anti-tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. Two separate formulations of cabozantinib have received regulatory approval to treat certain forms of kidney and thyroid cancer and are marketed for those purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ® capsules (U.S. and EU), respectively. Another Exelixis-discovered compound, COTELLIC® (cobimetinib), a selective inhibitor of MEK, has been approved in major territories including the United States and European Union, and is being evaluated for further potential indications by Roche and Genentech (a member of the Roche Group) under a collaboration with Exelixis. Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S. trademark.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
115
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : EXEL
Received SBIR $$
No

SBIR firms in the news

There are no news available.